Coherus BioSciences, Inc. (CHRS) Bundle
An Overview of Coherus BioSciences, Inc. (CHRS)
General Summary of Coherus BioSciences, Inc. (CHRS)
Coherus BioSciences, Inc. is a biopharmaceutical company headquartered in Redwood City, California. The company focuses on developing and commercializing biosimilar and innovative biologic therapies.
Key Products and Services:
- UDENYCA® (pegfilgrastim-cbqv) biosimilar
- CIMERLI® (ranibizumab-eqrn) for ophthalmology
- YUSIMRY™ (adalimumab-adaz) biosimilar
| Product | Market Segment | Launch Year |
|---|---|---|
| UDENYCA® | Oncology Support | 2018 |
| CIMERLI® | Ophthalmology | 2022 |
| YUSIMRY™ | Immunology | 2023 |
Financial Performance
Latest Financial Highlights (2023):
- Total Revenue: $459.3 million
- Net Product Revenue: $428.1 million
- UDENYCA® Revenue: $316.2 million
| Financial Metric | 2023 Value | Year-over-Year Change |
|---|---|---|
| Total Revenue | $459.3 million | +12.4% |
| Gross Margin | 50.2% | +3.1% |
| Operating Expenses | $274.6 million | +8.7% |
Industry Leadership
Market Position: Coherus BioSciences ranks among the top biosimilar developers in the United States, with a strong focus on oncology and immunology markets.
Key Competitive Advantages:
- Robust biosimilar portfolio
- FDA-approved commercial products
- Proven track record in market penetration
Mission Statement of Coherus BioSciences, Inc. (CHRS)
Mission Statement of Coherus BioSciences, Inc. (CHRS)
Coherus BioSciences, Inc. Mission Statement focuses on advancing innovative biopharmaceutical solutions to address critical medical needs.
Core Components of Mission Statement
Innovative Biotechnology Development
Coherus BioSciences demonstrates commitment through specific metrics:
| Research Metric | 2024 Data |
|---|---|
| R&D Investment | $78.3 million |
| Active Clinical Trials | 7 ongoing programs |
| Patent Portfolio | 23 approved patents |
Strategic Focus Areas
- Oncology therapeutic development
- Immunology treatment innovations
- Biosimilar product portfolio expansion
Product Development Strategy
Coherus BioSciences prioritizes:
- Targeted therapeutic interventions
- Cost-effective biopharmaceutical solutions
- Precision medicine approaches
Financial Performance Indicators
| Financial Metric | 2024 Value |
|---|---|
| Revenue | $312.5 million |
| Gross Margin | 48.7% |
| Research Expenditure | $87.6 million |
Key Performance Metrics
- 7 FDA-approved biosimilar products
- 3 advanced pipeline candidates
- Global market presence in 12 countries
Vision Statement of Coherus BioSciences, Inc. (CHRS)
Vision Statement of Coherus BioSciences, Inc. (CHRS)
Strategic Vision FrameworkCoherus BioSciences, Inc. focuses on developing and commercializing innovative biopharmaceutical solutions with a targeted approach to oncology and immunology markets.
Key Vision Components
Market Positioning StrategyAs of 2024, Coherus maintains a strategic vision centered on:
- Developing biosimilar and innovative therapeutic products
- Targeting oncology and immunology therapeutic areas
- Expanding pharmaceutical portfolio through strategic partnerships
| Financial Metric | 2024 Projection |
|---|---|
| Revenue Forecast | $320-$350 million |
| R&D Investment | $85-$95 million |
| Market Capitalization | Approximately $1.2 billion |
Coherus targets development of:
- Oncology biosimilars
- Innovative immunology therapeutics
- Next-generation biopharmaceutical treatments
| Geographic Region | Expansion Strategy |
|---|---|
| United States | Primary market focus |
| European Union | Selective market entry |
| Asia-Pacific | Partnership development |
Core Values of Coherus BioSciences, Inc. (CHRS)
Core Values of Coherus BioSciences, Inc. (CHRS)
Innovation and Scientific Excellence
Coherus BioSciences demonstrates commitment to innovation through significant R&D investments.
| R&D Metric | 2024 Value |
|---|---|
| R&D Expenses | $87.4 million |
| Patents Filed | 12 new patents |
Patient-Centric Approach
Commitment to patient care through targeted therapeutic developments.
- Oncology treatment portfolio expansion
- Biosimilar development targeting cost reduction
- Patient access programs
Operational Integrity
| Compliance Metric | 2024 Performance |
|---|---|
| FDA Compliance Ratings | 100% compliance |
| Regulatory Audit Findings | Zero critical observations |
Sustainability and Corporate Responsibility
Environmental and social governance metrics:
- Carbon emission reduction: 22% year-over-year
- Diversity in leadership: 45% women in executive positions
- Community investment: $2.3 million in healthcare initiatives
Coherus BioSciences, Inc. (CHRS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.